Clinical trials including SUSTAIN, STEP, and SELECT have collectively enrolled more than 100,000 patients treated over periods ranging from one to five years, generating an extensive body of evidence
Promise Pharmacy received disciplinary action from the Florida Board of Pharmacy in September 2020 for USP violations involving hazardous drug training, documentation gaps, and facility deficiencies
Consumers with the following priorities may wish to compare this model with traditional in-person care or other treatment pathways: Preference for FDA-approved products exclusively: Consumers who prefer to use only FDA-approved finished products that have undergone the agency's full premarket approval process can access branded GLP-1 medications such as Wegovy or Zepbound through a primary care physician or in-person specialist, where FDA-approved formulations can be prescribed and filled at traditional retail pharmacies
Wegovy injection and Wegovy tablets (semaglutide), Zepbound (tirzepatide), and Foundayo (orforglipron), approved April 1, 2026 under NDA 220934 as an oral tablet
Questions and Answers Withdrawal of Marketing Authorisation Application for Egrifta (tesamorelin)
